More accurately, they overly speculated based on dates. Intermediate biotech target dates are uncertain and unreliable, so speculating on them is very risky. And doing so with options is downright foolish unless limiting it to capital you're very comfortable with losing. Those complaining about "CEO lies" were careless.
The results are now very soon, and there's a good chance of positive Avatar results. With the recent market dip this week, short-dated AVXL call options are now relatively cheap, and a good speculative bet with a small amount of capital. Don't buy what you can't afford to lose. Those who've been melting down, stay away.
News 
Market Data 
Discover 
